Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29648201 | 0.79 | HPGD (0.55) | MEN1KMT2ACYP1A2CYP2A6NOTUM | |
| SCHEMBL1044845 | 0.79 | HPGD (0.55) | MEN1KMT2ACYP1A2CYP2A6NOTUM | |
| SCHEMBL678115 | 0.78 | MEN1 (0.50) | MEN1KMT2APOLBCYP1A2CYP2C9 | |
| SCHEMBL8164410 | 0.78 | MEN1 (0.50) | MEN1KMT2APOLBCYP1A2CYP2C9 | |
| SCHEMBL29946500 | 0.78 | MEN1 (0.50) | MEN1KMT2APOLBCYP1A2CYP2C9 | |
| SCHEMBL6949386 | 0.78 | MEN1 (0.50) | MEN1KMT2APOLBCYP1A2CYP2C9 | |
| SCHEMBL28735599 | 0.78 | HPGD (0.53) | MEN1KMT2ACYP1A2CYP2A6NOTUM | |
| Hydrochloric Acid SCHEMBL1977939 | 0.77 | MEN1 (0.49) | MEN1KMT2APOLBCYP1A2CYP2C9 | |
| SCHEMBL9627340 | 0.76 | HPGD (0.66) | MEN1KMT2APOLBCYP1A2CYP2C9 | |
| SCHEMBL677619 | 0.74 | MEN1 (0.50) | MEN1KMT2APOLBCYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022044-A1 | TRIAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LLC | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022044-A1 | TRIAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | MAPT, BACE1, APP | MEN1 2627/4885KMT2A 1376/4885POLB 3874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.